cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Novo Nordisk shares plunge after drug trial disappoints Novo Nordisk's CagriSema outperforms Ozempic – cagrisema phase 3 results 2025

doi: 10.5935/1518-0557.20130052 52 BuhlingKSchumacherAEulenburgCZLaakmannE

In and out quickly

It may be useful in certain medical situations, especially confirmed carnitine deficiency, but routine supplementation is not necessary for most healthy people

The consequences are significant: accelerated muscle loss, a soft flabby appearance despite weight loss, reduced metabolic rate, weakened immune function, hair loss, and poor recovery from exercise

Stopping is reasonable only if you've achieved your weight goal, sustained behavioral changes for months, and have a clear plan to prevent regain through diet and exercise